Xenon Pharmaceuticals

company in Burnaby, Canada

XENE Nasdaq ISIN CA98420N1050 SEC CIK 1582313 LEI 549300XV44Q9Z1MIPQ03
Follow Xenon Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$110.4M −21.5% vs same quarter last year
EPS, diluted −$1.11 +3.5% vs same quarter last year
Operating cash flow −$90.3M −25.9% vs same quarter last year
Revenue by quarter
$0
$7.5M
$0
$0
$0
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$400M−$300M−$200M−$100M$0$100MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$7.5M−$345.9M
FY24$0−$234.3M
FY23$0−$182.4M
FY22$9.4M−$125.4M
FY21$18.4M−$78.9M
FY20$32.2M−$28.8M
FY19$6.8M−$41.6M
FY18-−$34.5M
FY17$311K−$30.7M
FY16$1.8M−$23M
FY15$15.6M−$15.8M
FY14$28.4M$13M
FY13$27.4M$12M
FY12$14.3M−$4.3M
FY11--
MarginsShare of revenue
  • Operating margin
  • Net margin
−15000%−10000%−5000%0%5000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−4974.3%−4612.1%
FY24--
FY23--
FY22−1368.9%−1328.9%
FY21−428.4%−427.8%
FY20−97.3%−89.7%
FY19−627%−609.1%
FY18--
FY17−10474.3%−9872.7%
FY16−1376.4%−1275.5%
FY15−60.1%−101.1%
FY1439.1%45.9%
FY1335.5%44%
FY12−22%−30.1%
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0$100MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$279.9M
FY24−$184.5M
FY23−$156.7M
FY22−$103.9M
FY21−$71.6M
FY20−$50.8M
FY19−$6M
FY18−$35.2M
FY17−$29M
FY16−$19.8M
FY15−$18.7M
FY14−$1.3M
FY13−$3.5M
FY12$45M
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Xenon Pharmaceuticals
  • Healthcare median
−10000%−7500%−5000%−2500%0%2500%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearXenon PharmaceuticalsHealthcare median
FY25−4612.1%−30.6%
FY24-−47%
FY23-−58%
FY22−1328.9%−80.4%
FY21−427.8%−71.9%
FY20−89.7%−62.2%
FY19−609.1%−46.3%
FY18-−49.6%
FY17−9872.7%−45.9%
FY16−1275.5%−36%
FY15−101.1%−38.4%
FY1445.9%−35.5%
FY1344%−37.1%
FY12−30.1%−29.1%
FY11-−27.9%